Skip to main content
Equibles
ALHC logo

ALHC · Alignment Healthcare, Inc. · Metrics

Track ALHC — free

Use ALHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.35 -0.16 (-1.88%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.75B
Shares
207.44M
Volume · Oct 21 2.76M Avg daily vol (3M) 8.18M

ALHC metrics

90 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.51
Market cap
$1.75B

Price action

20 metrics
Price change (1W)
+2.5%
Price change (30D)
+2.2%
Price change (3M)
-60.4%
Price change (6M)
-60.5%
Price change (YTD)
-56.9%
Price change (1Y)
-51.1%
Trailing year
Price change (5Y)
-55.8%
52-week high
$24.56
52-week low
$7.55
Change from 52-week high
-65.4%
Change from 52-week low
+12.8%
Annualized volatility
69.4%
Annualized volatility (3M)
82.2%
Beta
0.4
RSI (14D)
42.6
Price vs SMA 50
-20.6%
Price vs SMA 200
-50.9%
Avg volume (3M)
8.18M
Relative volume
0.4
Average dollar volume
$87.49M

Company

3 metrics
Sector
Healthcare
Industry
Healthcare Plans
Shares outstanding
207.44M

Valuation

12 metrics
P / E (TTM)
42.6
Trailing earnings · reciprocal yield 2.4%
PEG ratio
0.3
EV / revenue
0.3×
reciprocal yield 328.2%
EV / EBITDA
16.1×
reciprocal yield 6.2%
EV / EBIT
25.4×
reciprocal yield 3.9%
P / sales
0.4×
reciprocal yield 258.2%
P / book
6.7
reciprocal yield 15.0%
FCF yield
10.0%
TTM · current market cap
Buyback yield
—
P / FCF
10.0
reciprocal yield 10.0%
P / operating cash flow
8.6
reciprocal yield 11.6%
Earnings yield
2.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.7×
reciprocal yield 133.9%
EV / revenue historical average (5Y)
0.9×
reciprocal yield 108.7%
EV / EBIT historical average (3Y)
419.0×
reciprocal yield 0.2%
EV / EBIT historical average (5Y)
419.0×
reciprocal yield 0.2%
EV / EBITDA historical average (3Y)
168.2×
reciprocal yield 0.6%
EV / EBITDA historical average (5Y)
168.2×
reciprocal yield 0.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
—
Operating margin
1.2%
Trailing 12 months
Net margin
0.9%
Gross profit (TTM)
—
Operating profit (TTM)
$55.00M
Net income (TTM)
$40.70M
Trailing 12 months
Diluted EPS (TTM)
$0.20
FCF margin
3.9%
Effective tax rate
-5.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.88

Growth

11 metrics
Revenue growth YoY
+31.6%
Year over year
Net income growth YoY
+133.4%
Revenue (TTM)
$4.58B
Trailing 12 months
EPS growth YoY
+142.9%
Shares change YoY
+2.6%
Year over year · more shares
Revenue CAGR (3Y)
+40.2%
Revenue CAGR (5Y)
+32.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
15.4%
Return on assets
3.2%
Debt / equity
1.2
Current ratio
1.7
EBITDA (TTM)
$86.50M
Free cash flow (TTM)
$177.51M
Quick ratio
1.7
Interest coverage
3.4
Net debt / EBITDA
-4.4
Return on invested capital
—
Trailing 12 months
Net cash
$377.65M
Latest balance sheet
Cash & equivalents
$693.45M
Total assets
$1.28B
Total debt
$324.06M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$205.55M
Capital expenditures (TTM)
$28.04M
R&D (TTM)
—
SG&A (TTM)
$487.92M
Stock compensation (TTM)
$61.53M
R&D / revenue
—
Stock compensation / revenue
1.3%

Ownership (13F)

9 metrics
13F filers
330
13F filer change QoQ
+35
Institutional ownership
108.0%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.8%
Holder tenure
12.4
Price vs estimated holder cost
+42.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.8%

Short interest

3 metrics
Short interest
11.4%
Latest settlement · 1.6 days to cover
Days to cover
1.6d
Short-squeeze score
52 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$13.71M
Insider-sentiment score
19 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1832466 CUSIP 01625V104 13F (30d) 29 filings 28 filers Visit website Investor relations